Financial Performance - For the twelve months ended June 30, 2023, the net loss was $8.8 million, primarily due to R&D, marketing, and other costs related to the commercialization of the medical qualification certification business[14]. - The company reported a net loss of $8.8 million for the twelve months ending June 30, 2023[54]. - Net loss decreased from $11.6 million to $8.8 million for the twelve months ended June 30, 2023, primarily due to costs related to the commercialization of medical credentialing and eBadge technology[1]. - The total comprehensive loss attributable to the company's owners was $8.5 million for the year, compared to $13.5 million in the previous year[8]. - Basic and diluted loss per share was reported at $0.020 for the year ending June 30, 2023[71]. - Operating loss for the twelve months ended June 30, 2023, was $6.3 million, compared to $4.5 million in the previous year[7]. - The company reported a pre-tax loss of $8.3 million for the twelve months ended June 30, 2023, down from $12.4 million in the prior year[6]. Revenue and Profitability - Total revenue increased from $40.7 million for the twelve months ended June 30, 2022, to $44.0 million for the twelve months ended June 30, 2023, representing an increase of 8.1% in average subscription fees[1]. - Gross profit rose from $35.3 million to $39.2 million, with a gross margin increase of 2.3% to 89.1% for the twelve months ended June 30, 2023[1]. Expenses - Research and development expenses amounted to $20.3 million for the twelve months ended June 30, 2023, compared to $19.5 million for the same period in 2022[1]. - Sales and marketing expenses increased to $5.2 million from $4.2 million year-over-year[5]. - General and administrative expenses rose to $24.3 million from $21.8 million year-over-year[5]. Assets and Liabilities - Total liabilities amounted to $62.6 million as of June 30, 2023, compared to $68.0 million as of June 30, 2022[51]. - The current liabilities net amount increased to $29.0 million as of June 30, 2023, compared to $19.1 million as of June 30, 2022[31]. - Current liabilities included borrowings of $24.0 million as of June 30, 2023, compared to $28.5 million as of June 30, 2022[51]. - Non-current liabilities included lease liabilities of $6.2 million as of June 30, 2023, down from $7.0 million the previous year[50]. - The company’s total equity and liabilities amounted to $58.6 million as of June 30, 2023, compared to $74.4 million the previous year[51]. - The company’s asset return rate was negative 13.3% for the twelve months ended June 30, 2023, showing no significant fluctuation compared to negative 13.2% for the same period in 2022[12]. Cash Flow and Working Capital - Cash and cash equivalents, along with restricted cash, amounted to approximately $23.7 million as of June 30, 2023[54]. - The company generated positive operating cash flow during the twelve months ending June 30, 2023[54]. - The company has undertaken measures to alleviate cash flow pressure, including reducing cash outflows for restricted share awards and not conducting any share buybacks[54]. - The company plans to maintain sufficient working capital for operations over the next twelve months starting from June 30, 2023[55]. Employee and Compensation - As of June 30, 2023, the company had 184 employees, an increase from 143 employees as of June 30, 2022[35]. - Total employee compensation, including director remuneration, amounted to $30.5 million for the twelve months ending June 30, 2023, compared to $19.5 million for the same period in 2022, reflecting a 56.4% increase[35]. - The company has implemented stock option plans and restricted share award plans to attract and retain key employees, promoting growth[35]. Investments and Financial Policies - The company has established a policy to limit investments in further developing medical personnel offices and new potential businesses[14]. - The company has adopted a code of conduct for securities trading by directors that is at least as stringent as the standard code[39]. - The company has not purchased, sold, or redeemed any of its listed securities during the reporting period[40]. - The company anticipates that the adoption of new accounting standards will not have a significant impact on its consolidated financial statements in future periods[48]. Accounting and Financial Reporting - The group capitalizes development costs as intangible assets and amortizes them on a straight-line basis over a period of 3 years[107]. - The group recognizes impairment losses when the carrying amount of an asset exceeds its recoverable amount[125]. - The group assesses whether all acquired assets and liabilities have been correctly identified during acquisitions[105]. - The group’s functional currency is the currency of the primary economic environment in which each entity operates, typically presented in USD[113]. - The group uses the straight-line method to amortize finite-lived intangible assets over their estimated useful lives[108]. - The group recognizes development costs as intangible assets when they meet specific criteria, otherwise, they are expensed as incurred[149].
中智全球(06819) - 2023 - 年度业绩